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ABSTRACT
Background
Highly active antiretroviral treatment (HAART) has only been recently recommended for HIV-
infected pregnant women requiring treatment for their own health in resource-limited settings.
However, there are few documented experiences from African countries. We evaluated the
short-term (4 wk) and long-term (12 mo) effectiveness of a two-tiered strategy of prevention of
mother-to-child transmission of HIV (PMTCT) in Africa: women meeting the eligibility criteria of
the World Health Organization (WHO) received HAART, and women with less advanced HIV
disease received short-course antiretroviral (scARV) PMTCT regimens.
Methods and Findings
The MTCT-Plus Initiative is a multi-country, family-centred HIV care and treatment program
for pregnant and postpartum women and their families. Pregnant women enrolled in Abidjan,
Co ˆte d’Ivoire received either HAART for their own health or short-course antiretroviral (scARV)
PMTCT regimens according to their clinical and immunological status. Plasma HIV-RNA viral
load (VL) was measured to diagnose peripartum infection when infants were 4 wk of age, and
HIV final status was documented either by rapid antibody testing when infants were aged   12
mo or by plasma VL earlier. The Kaplan-Meier method was used to estimate the rate of HIV
transmission and HIV-free survival. Between August 2003 and June 2005, 107 women began
HAART at a median of 30 wk of gestation, 102 of them with zidovudine (ZDV), lamivudine (3TC),
and nevirapine (NVP) and they continued treatment postpartum; 143 other women received
scARV for PMTCT, 103 of them with sc(ZDVþ3TC) with single-dose NVP during labour. Most
(75%) of the infants were breast-fed for a median of 5 mo. Overall, the rate of peripartum HIV
transmission was 2.2% (95% confidence interval [CI] 0.3%–4.2%) and the cumulative rate at 12
mo was 5.7% (95% CI 2.5%–9.0%). The overall probability of infant death or infection with HIV
was 4.3% (95% CI 1.7%–7.0%) at age week 4 wk and 11.7% (95% CI 7.5%–15.9%) at 12 mo.
Conclusions
This two-tiered strategy appears to be safe and highly effective for short- and long-term
PMTCT in resource-constrained settings. These results indicate a further benefit of access to
HAART for pregnant women who need treatment for their own health.
The Editors’ Summary of this article follows the references.
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Mother-to-child transmission (MTCT) of HIV-1 is esti-
mated to be the cause of at least 90% of paediatric HIV
infections, with more than 700,000 children newly infected in
2006 worldwide [1]. New HIV infections in children are
becoming increasingly rare in Western Europe (200 reported
in 2004) and the United States (300) [1,2]. In these relatively
resource-rich contexts, the availability of highly active
antiretroviral therapy (HAART), usually three antiretroviral
(ARV) drugs during pregnancy, in combination with the
avoidance of breast-feeding and with elective caesarean
section, has reduced the transmission rate to less than 2%
and resulted in the near elimination of MTCT [1–3].
In sub-Saharan Africa, progress has been made in the last
few years toward expanding prevention of MTCT (PMTCT)
programs based on trial ﬁndings that have demonstrated the
efﬁcacy of generally simpler and shorter ARV prophylactic
regimens than those used in industrialized countries [4–9].
This expansion has been based primarily on the use of single-
dose nevirapine (sdNVP) and, to a lesser extent, short-course
antiretroviral (scARV) regimens of one or two drugs
administered at the end of pregnancy and followed with
sdNVP to prevent peripartum transmission. Postnatal trans-
mission of HIV, resulting in 9.8 new HIV infections per 100
child-years of breast-feeding overall, and occurring most
frequently in women with low CD4 T cell counts [10], reduces
the long-term overall efﬁcacy of peripartum ARV regimens
[11].
World Health Organization (WHO) had set a target of
treating three million individuals in the developing world
with HAART by 2005 [12], and the United Nations General
Assembly Special Session on HIV/AIDS committed countries
to reducing by 20% the proportion of infants infected with
HIV by 2005 [13]. In this context, WHO guidelines for the
prevention of perinatal transmission in low-resource settings
now recommend using HAART for pregnant women in need
of ARV therapy (ART) for their own health [14]. This policy
was agreed upon in recognition of the potential impact of
HAART on decreasing morbidity and mortality in women
with advanced HIV disease, as well as its potentially profound
effect on preventing peripartum and postnatal HIV infection.
Currently, access to HAART for pregnant women in low-
income countries is limited, and there are few documented
experiences from African countries [15]. Although HAART is
widely used for peripartum PMTCT in industrialized coun-
tries [2,3,16], its efﬁcacy and safety have not been fully
assessed in resource-limited settings characterised by high
HIV seroprevalence, and few data are available to assess the
impact of ART on postnatal transmission.
We evaluated a two-tiered PMTCT strategy in pregnant
women enrolled at the MTCT-Plus Initiative care and
treatment program in Abidjan, Co ˆte d’Ivoire: on the basis
of their medical status (CD4 T cell count and WHO stage)
they were given either HAART or scARV for PMTCT.
HAART was targeted at pregnant women with advanced
HIV disease who met WHO eligibility criteria for treatment
and scARV regimens for PMTCT were prescribed to women
with less advanced HIV disease. We report the safety of
HAART in pregnant women and the 4 wk and 12 mo
outcomes for infant HIV infection and mortality for this
stepped PMTCT strategy.
Methods
Study Design and Participants
This observational cohort included women enrolled in the
MTCT-Plus Initiative, a multi-country, comprehensive HIV
care and treatment program for pregnant and postpartum
women and their families built on existing PMTCT services. It
provides pregnant and postpartum women with holistic,
family-centred HIV care including HAART to the woman, her
partner, and her children [17]. Pregnant women identiﬁed as
HIV-infected at two community-based antenatal clinics in
two low-income urban districts of Abidjan were referred for
enrolment into the MTCT-Plus program. The study popula-
tion included all HIV-infected pregnant women and their
live-born infants enrolled between August 2003 and April
2005 and followed until a ﬁnal paediatric HIV status could be
determined. Women were divided into two groups. The ﬁrst
cohort included the HIV-infected pregnant women who were
eligible for HAART based on WHO criteria (at high risk of
transmission); the second cohort included HIV-infected
pregnant women who were not eligible for HAART and
received sc-PMTCT (with low risk of transmission).
The MTCT-Plus program was reviewed by the institutional
review board (IRB) from Columbia University in 2000
(principal sponsor) and was not considered a research project
but rather a demonstration program in the context of the
ARV roll-out. Informed consent was not required by the
Columbia IRB.
Antiretroviral Regimens
Upon enrolment, all participants were screened for
HAART eligibility, deﬁned from August 2003 to December
2004 as: WHO clinical stage 4 irrespective of CD4 T cell
count; WHO stage 2 or 3 and CD4 T cell count   350 cells/
mm
3; or CD4 T cell count , 200 cells/mm
3. These criteria
were revised by the MTCT-Plus Initiative in January 2005 to
be in compliance with WHO 2005 PMTCT guidelines and to
avoid the side effects reported with NVP especially in
pregnant women with CD4 T cell count . 250 cells/mm
3
[18]; from that time forward, women with WHO stage 2 and
CD4 T cell count , 350 cells/mm
3 were no longer considered
eligible for HAART.
Other criteria taken into account for deciding to initiate
HAART were the absence of medical contraindications to
HAART as well as major barriers to adherence. Pregnant
women who met eligibility criteria initiated HAART as early
as 24 wk of gestation according to the last menstruation date,
usually with zidovudine (ZDV), lamivudine (3TC) and nevir-
apine (NVP). Treatment continued during labour and
postnatally. Pregnant women who were not eligible for
HAART received validated scARV prophylactic regimens,
usually sc(ZDVþ3TC) from 32 wk of gestation (until 3 d
postpartum) and sdNVP in labour [9,19], or scZDV from 28
wk, or sdNVP alone, or both scZDV and sdNVP [4,7–9,20]. All
infants received ZDV syrup for 7 d and sdNVP syrup on day 3
irrespective of the maternal drug regimen.
Follow-Up Procedures
Clinical classiﬁcation using the WHO staging system was
performed by the physicians at enrolment into the MTCT-
Plus program and at each subsequent visit.
Women either used breast milk substitutes if feasible and
affordable following WHO guidelines [21] or were encour-
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mo and initiate early weaning from 4 mo onwards. Caesarean
section was only performed for emergencies. Baseline
adherence and psycho-social assessments were done before
initiation of HAART, and followed by weekly visits for 8 wk
using a standardized checklist of clinical symptoms to detect
side effects and ensure adherence. A more detailed clinical
evaluation, including symptom review, physical examination,
and review of medication adherence was conducted monthly
following MTCT-Plus clinical guidelines [22]. Adherence was
assessed by physicians or nurses on the basis of a self report
consisting of the number of pills taken by the women during
the last 7 d preceding each schedule visit (all, most, few,
none). Severe adverse events were classiﬁed according to
international guidelines [23].
Laboratory Procedures
All blood samples of pregnant women who agreed to test
were screened on site for HIV antibodies according to a
validated algorithm described elsewhere [24]. CD4 T cell
count was measured upon enrolment and at intervals of 6 mo.
Hepatic and renal functions were measured prior to HAART
initiation; liver function tests were repeated 2 wk after
treatment initiation and monthly throughout pregnancy for
women on HAART. Additional laboratory evaluation was
restricted to patients with clinical indications.
Laboratory tests were done at a central reference labo-
ratory (CeDReS, Abidjan) certiﬁed by regional and interna-
tional quality assurance programs.
The CD4 T cell count and percentage were measured in the
antenatal period at the enrolment visit and thereafter every 6
mo after the initiation of the treatment using a dual-platform
ﬂow-cytometry technique with an automated blood cell counter
(MaxM, Beckman Coulter, http://www.beckmancoulter.com/) for
absolute lymphocyte count and a ﬂow cytometer (FACScan,
Becton Dickinson, http://www.bdbiosciences.com/) for measur-
ing the percentage of CD4 T cells (CD4%). Absolute CD4 T cell
count was then calculated multiplying the CD4% by the total
lymphocyte count. The laboratory quality control procedures
included: (i) daily internal controls for both the automated
blood cell counter (Coulter 5C cell control, Beckman Coulter)
and the ﬂow cytometer (BD multi-check control, Becton
Dickinson); (ii) participation in two international assurance
quality programs (UK-NEKAS and QASI).
Plasma HIV-RNA viral load (VL) testing for the early
diagnosis of paediatric HIV infection was performed using a
quantitative real-time RT-PCR technique targeted at the
HIV-1 LTR gene as previously validated [25]. The quantiﬁca-
tion limit of this method was 300 copies/ml with 200 llo f
plasma. All infants were tested at 4 wk of age, and if positive,
conﬁrmed with repeat VL testing at 6 wk. Infants with two
positive tests were classiﬁed as infected peripartum. Infants
with a negative VL test at 4 wk of age were classiﬁed as
uninfected peripartum and were subsequently tested at 12
mo by rapid HIV antibody testing. If the antibody test at 12
mo was positive, we performed a second test for conﬁrmation
at 15 mo or later. The HIV infection status of the children
who stopped follow-up just after being tested HIV antibody-
positive at 12 mo or who had ceased breast-feeding under the
age of 2 mo was conﬁrmed by VL testing. HIV antibody-
negative or VL-negative children were classiﬁed as unin-
fected. Postnatal transmission was deﬁned as a negative HIV
PCR from a ﬁrst sample at age 30–180 d followed by a positive
VL or antibody test at 12 or 15 mo.
Statistical Analysis
Group comparisons according to ARV regimens used
Student t-test or nonparametric Mann-Whitney test for
quantitative variables, and Chi
2 test or Fisher exact test for
qualitative variables. The ﬁrst-live born child was used for
analysis in the case of multiple births.
Two survival analyses were conducted using two different
outcomes in children: HIV infection or HIV-free survival
(which is deﬁned as ending at the occurrence of HIV
infection or death, whichever came ﬁrst). Cumulative trans-
mission risks of HIV and (HIV or death) were estimated using
both Turnbull method and Kaplan-Meier probabilities. As
results were similar (unpublished data), Kaplan-Meier esti-
mates were retained to allow for comparisons between groups
using the log-rank test. For survival analysis, time to infection
was estimated up to the ﬁrst positive test for peripartum cases
or to the midpoint date between the last negative test and the
ﬁrst positive test for the postnatal cases. Results were
expressed in percentages with their 95% conﬁdence intervals
(95% CIs). Determinants of HIV infection and (HIV or death)
were explored using a Cox model with the following variables:
maternal age, ARV regimen, WHO staging, CD4 T cell count,
haemoglobinemia, infant feeding practice from birth, birth
weight, and child gender. A stepwise descendant multivariate
analysis included all variables with p , 0.25 in the univariate
analysis. Statistical analyses were processed with Stata
software, version 9.0 (Stata, http://www.stata.com/).
Results
Characteristics of Study Population
Between August 2003 and April 2005, 261 pregnant women
with conﬁrmed HIV-1 infection were enrolled and 250 were
prescribed ARVs before and/or during delivery: 143 (57%)
received scARVs and 107 (43%) received a HAART regimen.
Three of the original 261 women were lost to follow-up and
eight delivered before an ARV regimen could be initiated
(Figure 1).
Maternal baseline characteristics are summarized in Table
1. Overall, median maternal age was 27 y (interquartile range
[IQR] 24–31 y) and median gestational age at the time of
enrolment was 30 wk (IQR 25–33 wk). Median CD4 T cell
count was 338 cells/mm
3 (IQR 206–488 cells/mm
3) and 44
(17.6%) of the women were classiﬁed as WHO clinical stage 3
or 4.
HAART eligibility criteria were met by 104 women; in
addition, three women received HAART at the discretion of
the physician without fulﬁlling WHO/MTCT-Plus criteria.
The median CD4 T cell count of all 107 women who received
HAART was 189 cells/mm
3 (IQR 135–266 cells/mm
3); 33
(30.9%) of these women were at WHO stage 3 or 4, and 58
(54.1%) had a CD4 T cell count , 200 cells/mm
3 (Table 1).
Most (102 [95.3%]) received a combination of ZDV, 3TC, and
NVP. Five women (4.7%) were prescribed stavudine (d4T),
3TC, and NVP (Figure 1). HAART was initiated at a median of
30 wk of gestation (IQR 27–33 wk) (Table 2). Median duration
on HAART until delivery was 74 d (IQR 48–91 d). Of the 93
women treated with HAART   1 mo before delivery, 91%
reported complete adherence. All infants born to HAART-
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syrup.
Among the 143 pregnant women who received scARV for
PMTCT, the median CD4 T cell count was 467 cells/mm
3 (IQR
368–602 cells/mm
3) and 11 (7.7%) had WHO stage 3 HIV
disease at the time of enrolment (Table 1). Median gestational
age at prophylaxis initiation was 34 wk (IQR 32–36 wk) and
median number of days on scARV drug regimens was 46 d
(IQR 31–65 d) (Table 2); 103 women (72.0%) received
sc(ZDVþ3TC) with sdNVP during labour, 26 (18.2%) scZDV
with sdNVP, and 14 (9.8%) sdNVP alone (Figure 1).
Among the 241 women who had pregnancy outcomes for
the analysis (Figure 1), 172 (71.3%) initiated breast-feeding at
birth (62 in the HAART group and 110 in the scARV for
PMTCT group). The overall median duration of breast-
feeding was 5.4 mo (IQR 4.0–6.8 mo) and was slightly longer
in the scARV for PMTCT group (5.8 mo) than in the HAART
group (4.6 mo) (p ¼ 0.010).
Effectiveness of ARV Regimens at 4 Weeks and 12 Months
Excluding the second child of ﬁve multiple births, there
were 241 pregnancy outcomes for the present analysis (Figure
1). Four (3.9%) and 6 (4.3%) stillbirths were reported in the
HAART and the scARV for PMTCT groups, respectively (p ¼
1.00). HIV infection status could not be determined for six
live-born children (three in each group), who died in the ﬁrst
week of life before a blood sample could be collected (Figure
1). Overall, among the 231 neonates at risk of HIV infection,
172 (75.1%) initiated breast-feeding, of whom 168 were tested
for HIV at the age of 4 wk. Overall HIV infection status could
Figure 1. Study Profile
Population included in the estimation of the rate of mother-to-child transmission of HIV in the MTCT-Plus program in Abidjan, Co ˆte d’Ivoire, August
2003 through October 2006. Among the six HIV-infected infants, three had received single dose nevirapine (sdNVP), two short courses of ZDVþsdNVP,
and one short course of ZDVþ3TCþsdNVP for PMTCT.
doi:10.1371/journal.pmed.0040257.g001
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were diagnosed as HIV-infected (Table 3): ﬁve were diagnosed
by the age of 4 wk, three more by the age of 3 mo, and the
remaining four by the age of 12 mo (Figure 2). The overall
probability of conﬁrmed peripartum HIV infection was 2.2%
(95% CI 0.3%–4.2%): 1.0% (95% CI 0.0%–3.1%) in the
HAART group and 3.1% (95% CI 0.1%–6.1%) in the scARV
for PMTCT group (Table 4). At 12 mo, 5.7% (95% CI 2.5%–
9.0%) of the infants were diagnosed as HIV-infected: 3.3%
(95% CI 0.0%–6.9%) in the HAART group and 7.5% (95% CI
2.8%–12.3%) in the scARV for PMTCT group (log-rank test, p
¼ 0.18). No statistically signiﬁcant difference was found
according to the infant feeding practice (p ¼ 0.48). In
multivariate analysis, low birth weight (,2,500 g) was the
only factor associated with acquisition of HIV infection, with
an adjusted hazard ratio of 5.63 (95% CI 1.62–19.49, p ¼
0.006), controlling for infant feeding practice, gender,
maternal ARV drug regimen, WHO staging, absolute CD4 T
count, haemoglobin level, and age at baseline.
Postnatal Transmission
The postnatal transmission risk was estimated among all
children who were RT-PCR HIV-negative at age 4 wk (Figure
2). Subsequent pediatric diagnostic assessment was not
possible for 21 children: 11 were lost to follow-up (ten in
the scARV for PMTCT group and one in the HAART group),
Table 1. Maternal Characteristics of HIV-Infected Pregnant Women Having Initiated an ARV Regimen for PMTCT in the MTCT-Plus
Program, Abidjan (Co ˆte d’Ivoire), 2003–2005
Category Group Total (n ¼ 250) Treatment: HAART (n ¼ 107) Treatment: scARV (n ¼ 143) p-Value
Age, y Median (IQR) 27 (24–31) 28 (25–31) 27 (23–30) 0.02
Gestational age at enrolment, wk Median (IQR) 30 (25–33) 27 (24–32) 32 (28–33) ,0.001
,28 88 (35.2) 56 (52.3) 32 (22.3) ,0.001
28–32 57 (22.8) 24 (22.4) 33 (23.1)
.32 105 (42.0) 27 (25.3) 78 (54.6)
WHO staging Stage 1 105 (42.0) 15 (14.0) 90 (62.9) ,0.001
Stage 2 101 (40.4) 59 (55.1) 42 (29.4)
Stage 3 41 (16.4) 30 (28.1) 11 (7.7)
Stage 4 3 (1.2) 3 (2.8) 0 (0.0)
CD4 T cell count at enrolment, cells/mm
3 Median (IQR) 338 (206–488) 189 (135–266) 467 (368–602) ,0.001
,200 58 (23.2) 58 (54.1) 0 (0.0) ,0.001
200–350 74 (29.6) 47 (44.0) 27 (18.9)
350–500 61 (24.4) 2 (1.9) 59 (41.3)
 500 57 (22.8) 0 (0.9) 57 (39.8)
CD4 T cell count at enrolment, % Median (IQR) 22.0 (16.0–28.9) 15.9 (10.7–19.9) 27.1 (23.2–34.0) ,0.001
,15 48 (19.2) 43 (40.2) 5 (3.5) ,0.001
15–20 45 (18.0) 38 (35.5) 7 (4.9)
20–25 60 (24.0) 20 (18.7) 40 (27.9)
 25 97 (38.8) 6 (5.6) 91 (63.7)
Haemoglobin level, g/dl Median (IQR) 9.5 (8.9–10.1) 9.7 (8.8–10.7) 9.5 (8.9–10.1) 0.250
Eligible for HAART n (%) 105 (42.0) 104 (97.2)
a 1 (0.7)
b ,0.001
Unless otherwise indicated, data are presented as n (%).
aThree women received HAART based on the physician indication only (CD4 T cells ,355 cells/mm
3 and history of multiple stillbirths) without fulfilling WHO/MTCT-Plus eligibility criteria.
bOne pregnant woman was eligible for HAART according to WHO criteria, refused to take HAART for herself but accepted an ARV short-course prophylactic regimen for PMTCT.
doi:10.1371/journal.pmed.0040257.t001
Table 2. Antiretroviral Drug Regimen Characteristics in Pregnant Women Enrolled in the MTCT-Plus Program in Abidjan (Co ˆte d’Ivoire),
2003–2005
Category Characteristics Total HAART scARV p-Value
Initiation, in weeks of amenorrhea n 250 107 143
Median (IQR) 32 (29–34) 30 (27–33) 34 (32–36) ,0.001
,28, n (%) 52 (20.8) 52 (48.6) — ,0.001
28–31, n (%) 72 (28.8) 18 (16.8) 54 (37.8)
32–35, n (%) 101 (40.4) 34 (31.8) 67 (46.8)
 36, n (%) 25 (10.0) 3 (2.8) 22 (15.4)
Duration of treatment until delivery, d
a n 241 103 138
Median (IQR) 55 (38–78) 74 (48–91) 46 (31–65) 0.001
,30, n (%) 43 (17.8) 10 (9.7) 33 (23.9) ,0.001
30–90, n (%) 162 (67.2) 66 (64.1) 96 (69.6)
a88 women in the HAART group continued antiretroviral treatment until at least the final paediatric HIV diagnosis.
doi:10.1371/journal.pmed.0040257.t002
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six in the HAART group). The deﬁnitive HIV infection status
could not be determined for ﬁve children who were antibody-
negative but still breast-fed at 12 mo of age. A total of 191
infants were thus included in this analysis (87 in the HAART
group and 104 in the scARV for PMTCT group) including 138
breast-fed infants (52 in the HAART group and 86 in the
scARV for PMTCT group). The median duration on HAART
in breast-feeding women was 14.9 mo (IQR 14.5–16.2 mo)
when the ﬁnal paediatric HIV status was ascertained. Overall,
four infants had a conﬁrmed postnatal infection (2.3% [95%
CI 0.8%–7.3%]). In the HAART group, one case of postnatal
infection was identiﬁed among 52 infants (1.9% [95% CI
0.04%–10.2%]) breast-fed for a median of 4.7 mo (IQR 3.3–
6.3 mo). In the scARV for PMTCT group, three cases of
postnatal infection were identiﬁed among 86 infants (3.5%
[95% CI 0.7%–9.9%]) breast-fed for a median of 5.7 mo (IQR
4.3–7.1 mo). If we hypothesize that the three cases with
unknown timing are possible postnatal cases, the rate of
postnatal transmission could be 3.8% (0.4%–12.9%) in the
HAART group and 5.7% (1.8%–12.7%) in the PMTCT group.
No case of postnatal infection was identiﬁed among the 53
infants who were formula fed (upper limit of 95% CI, 6.7%).
One death of an HIV-infected formula-fed infant was
reported (Table 5).
12-Month Infant HIV-Free Survival and Death According to
Maternal ARV Regimens
The overall probability of HIV infection or death among
infants aged 12 mo of all women enrolled in this study was
11.7% (95% CI 7.5%–15.9%); the probability was 11.2% (95%
CI 5.0%–17.4%) among infants born to HAART-treated
women, and 12.1% (95% CI 6.4%–17.9%) among infants
whose mothers received scARV for PMTCT only (log-rank
test, p ¼ 0.90) (Table 4). In multivariate analysis, two factors
were associated with the occurrence of HIV infection or
death (n¼231): low birth weight (adjusted hazard ratio¼3.71
[95% CI 1.53–9.03], p¼0.004) and female sex (adjusted hazard
ratio ¼ 0.35 [95% CI 0.14–0.88], p ¼ 0.035), after controlling
for infant feeding practice, maternal ARV drug regimen,
WHO staging, absolute CD4 T count, haemoglobin level, and
age at baseline.
A total of 18 deaths were reported in this cohort: of 99
infants born to woman who had initiated HAART during
pregnancy, ten (10.1%) died, and among 132 infants who
were born to women who received short-course antiretroviral
prophylaxis, eight (6.0%) died. The data on infant mortality
are summarized according to the maternal ARV regimen in
Table 5. Twelve of the 18 deaths occurred in a medical facility
where a plausible cause was recorded. Due to the intensive
follow-up of mothers on HAART, eight out of the ten infant
deaths in this group were documented, compared to only
four of the eight deaths in the scARV for PMTCT group.
Maternal Adverse Events
As detailed in Table 6, nine (8.4%) of 107 pregnant women
initiating HAART required one change to their ARV regimen
before delivery. One woman was changed from NVP to
efavirenz at week 6 of treatment (gestational age 32 wk) after
diagnosis of tuberculosis. Eight women (7.5%) developed
grade 3 or 4 adverse events attributed to HAART: ﬁve women
developed grade 3 mucocutaneous rash attributed to NVP
and were switched to nelﬁnavir, and two women developed
grade 4 liver toxicity attributed to NVP, with alanine
aminotransferase levels over 50 times and over 5 times the
upper limit of normal value, respectively in the two groups of
women; one woman developed severe anaemia attributed to
ZDV. All events resolved with drug changes and no deaths
were reported. In the cohort of women receiving scARV for
PMTCT, no grade 3 or 4 toxicities were observed and no ART
changes were made.
Neonatal Adverse Events
As shown in Figure 1, the frequency of perinatal deaths
(stillbirths and neonatal deaths in the ﬁrst 28 d of life) was
comparable in the HAART and scARV for PMTCT groups:
6.7% and 5.6%, respectively (p ¼ 0.80). No signiﬁcant
difference in the rates of premature births (gestational age
Table 3. Description of the 12 Cases of Paediatric HIV Infection in the MTCT-Plus Program in Abidjan (Co ˆte d’Ivoire), 2003–2006
ID # Maternal
WHO Stage
Absolute CD4 T
Cell Count (%)
ARV Regimen Duration of
Exposure
a
Sex of
Infant
Birth Weight,
Grams
Infant
Feeding
Death Timing of
HIV Infection
11109 2 283 (18.9) ZDV/3TC/NVP 29 Female 2,700 BF No Unknown
b
11487 2 309 (15.9) ZDV/3TC/NVP 88
c Male 2,100 FF Day 59 Peripartum
11751 4 242 (18.8) ZDV/3TC/NVP 52 Male 2,000 BF No Postnatal
11002 1 433(21.8) sc(ZDV/3TC)þsdNVP 55 Male 3,600 BF No Postnatal
11775 2 363 (14.0) Sc(ZDV/3TC)þsdNVP 23 Male 2,600 BF Day 60 Peripartum
11417 2 386 (11.5) scZDVþsdNVP 48 Male 2,400 BF No Unknown
b
11591 2 391 (23.7) scZDVþsdNVP 19 Male 2,100 BF Day 305 Postnatal
11603 2 529 (26.9) scZDVþsdNVP 92 Female 3,000 BF No Unknown
b
11443 3 738 (23.7) sdNVP 1 Female 2,915 FF No Peripartum
11539 1 946 (44.1) sdNVP 1 Male 2,860 BF No Postnatal
11378 1 522 (32.0) sdNVP 1 Female 3,350 BF No Peripartum
11589 1 739 (31.8) sdNVP 1 Male 2,460 BF No Peripartum
aExposure to antiretroviral drugs until delivery.
bUnknown: first test positive between D60 and D90.
cTreatment was stopped 2 wk before delivery owing to the diagnosis of tuberculosis.
BF, breast-feeding; FF, formula feeding
doi:10.1371/journal.pmed.0040257.t003
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HAART and Pregnancy in Africa,37 wk) was noted between the two groups (7.8% and 7.9%
respectively, p ¼ 1.00). However, a higher proportion of low
birth weight (,2,500 g) was observed in neonates whose
mothers had received HAART, 26.3% compared with 12.4%
among those having received a scARV for PMTCT regimen (p
, 0.001). These differences persisted after adjusting for
maternal body mass index, CD4 T cell count, and WHO
clinical stage.
Discussion
We evaluated a two-tiered PMTCT strategy in which
treatment was selected based on maternal medical status (as
indicated by CD4 T cell count and WHO staging) in a West
African population. HAART was prescribed to pregnant
women with advanced HIV disease who met WHO eligibility
criteria based on their own health status, whereas short-
course various combinations of ARV regimens for PMTCT
were given to pregnant women with less advanced HIV
disease, who did not qualify for HAART. Three-quarters of
the infants were breast-fed, for a median of 5.4 mo. Overall,
the rate of peripartum HIV transmission was 2.2%, the
cumulative rate of infant HIV infection at 12 mo was 5.7%,
and the 12-mo HIV-free survival was 88.3%, without
measurable differences between the two groups.
The rate of peripartum MTCT that we observed in women
on HAART was very low (1.0%), similar to rates reported
from industrialized countries [2,3], despite a later identiﬁca-
tion of HIV infection during pregnancy, and a relatively short
duration of HAART prior to delivery. In the Women and
Infants Transmission Study in the US, HIV-1 transmission
rate was 1.2% in infants whose mothers had received HAART
but did not breast-feed [3]. Similarly, the European Collab-
orative Study Group reported the decline of MTCT trans-
mission rates from 15.5% in 1994, to 5.1% in 1997–1998, and
down to 0.99% in 2001–2002, i.e., when HAART became more
widely used [2].
The maternal and PMTCT beneﬁts of HAART initiated
during pregnancy that have been described in the industrial-
ized world may differ for populations from sub-Saharan
Africa because of the wider spectrum of opportunistic
diseases, the deeper level of immunodeﬁciency at which they
Figure 2. Postnatal HIV-1 Transmission
Profile of postnatal transmission study in the MTCT-Plus Program in Abidjan, Co ˆte d’Ivoire, August 2003 through October 2006
*Upper limit of 95% confidence interval.
doi:10.1371/journal.pmed.0040257.g002
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HAART and Pregnancy in Africaoccur [26], and the poorer nutritional background and
obstetrical conditions. In the DREAM cohort in Mozambique
where formula feeding was systematic, pregnant women
initiated a ZDV/NVP/3TC HAART combination at 25 wk of
gestation, irrespective of clinical or immunological staging;
the rate of HIV transmission from mother to infant was 1.2%
at infant age of 1 mo [27]. HAART was continued in this
cohort up to 6 mo postdelivery for those not requiring
therapy for their own health, while the others continued
treatment indeﬁnitely. We observed a comparable 1 mo of
age rate of transmission with a more targeted prescription of
HAART. As emphasized in the recently published WHO
PMTCT guidelines, it is critically important that pregnant
women who are eligible for HAART receive such treatment
for the sake of their own health as well as for reducing MTCT
[14]. Women with advanced HIV disease are at the highest
risks both for HIV-related morbidity and mortality and for
transmitting HIV to their child [28]. By decreasing the
mother’s plasma HIV VL and enhancing immune function,
a targeted HAART both treats the mother’s own HIV
infection and reduces dramatically the likelihood of HIV
transmission to the newborn. If HAART is used for PMTCT in
women not requiring it for their own health, however, the
potential risk to the woman’s health of interrupting HAART
after delivery and the potential risks of continuous HAART
exposure to uninfected infants are unclear.
We observed low rates of postnatal transmission in both
HAART-treated women and those receiving scARV for
PMTCT only. These results were observed in conditions of
short breast-feeding exposure with an overall median
duration of 5.4 mo. We observed one case of postnatal HIV
transmission among 52 breast-fed infants of HAART-treated
mothers and 3/86 among the breast-fed infants of women on
scARV regimens. There was no statistically signiﬁcant differ-
ence between the two groups, although sample size was
limited; this study was not designed to answer the question
‘‘does HAART substantially reduce postnatal transmission
risk? While HAART might diminish postnatal MTCT because
it suppresses cell-free HIV RNA in breast milk, other data
counteract this hypothesis [29]. Further studies are needed to
document the long-term safety and efﬁcacy of HAART for
the prevention of breast-feeding–associated HIV transmis-
sion, including among children breast-fed for long periods.
The universal use of HAART in HIV-infected pregnant
women irrespective of their clinical or immune status could
have several advantages, as shown in resource-rich countries.
It avoids using scARV prophylactic regimens, which though
effective in reducing MTCT, do not beneﬁt the women’s
health and are associated with some risk of development of
HIV resistance in the mother and infant, particularly with
sdNVP [19,30]. However, in low-resource settings, many
challenges hinder the universal use of HAART for all
pregnant women, including limited access to ARVs, uncertain
effects on maternal health from the short-term use of
HAART with postpartum interruption, and toxicity concerns
about NVP-containing HAART in women with higher CD4 T
cell counts [18,31]. It is therefore reassuring that the selective
use of HAART by HIV-infected pregnant women with
advanced disease, and scARV for PMTCT by pregnant women
with less advanced disease yield equivalent results in terms of
HIV-free survival in their infants. Furthermore, the use of a
ZDVþ3TC postpartum ‘‘tail’’ for 7 d reduces the risk of
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HAART and Pregnancy in Africaacquiring viral resistance in women receiving scARV for
PMTCT including sdNVP [19,32].
We observed a relatively low rate of severe adverse events
in HAART-treated HIV-infected pregnant women. Adverse
events that did occur were rapidly resolved with appropriate
drug management, and unexpected toxicities were absent;
together these observations suggest that HAART during
pregnancy for women with advanced disease is reasonably
safe. Of note, this study did not address the question of the
use of NVP-based HAART in women with high CD4 T cell
counts. The fact that 7.5% of the women developed toxicities
requiring a change of ARV drugs highlights the importance
of careful monitoring of pregnant women on HAART.
Clinical monitoring can detect many adverse events even
without laboratory results: in this study mucocutaneous
rashes constituted more than two-thirds of the maternal
Table 5. Description of the Occurrence of Pediatric Death in the MTCT-Plus Program in MTCT-Plus Program, Abidjan (Co ˆte d’Ivoire),
2003–2006
Infant
ID
Age at Death
(Day Postpartum)
Mother’s PMTCT
Regimen
Cause of Death HIV Status
Week 4
Infant Feeding
at Birth
11129 D1 HAART ND Not tested BF
11036 D4 HAART ND Not tested BF
11615 D24 HAART Neonatal infection Not tested BF
11354 D55 HAART SIDS Negative BF
11487 D59 HAART Epistaxis Positive FF
11328 D62 HAART Anaemia Negative BF
11012 D 72 HAART Isolated fever Negative BF
11232 D135 HAART Congenital abnormalities Negative BF
11102 D160 HAART Respiratory distress Negative BF
11263 D495 HAART Anaemia Negative BF
11733 D0 scZDVþsdNVP ND Not tested BF
11219 D0 sc(ZDVþ3TC)þsdNVP ND Not tested BF
11015 D1 sc(ZDVþ3TC)þsdNVP ND Not tested Not specified
11139 D1 sc(ZDVþ3TC)þsdNVP ND Not tested Not specified
11376 D123 sc(ZDVþ3TC)þsdNVP Convulsions Negative BF
11711 D178 sc(ZDVþ3TC)þsdNVP Respiratory distress Negative BF
11619 D274 scZDVþsdNVP Respiratory distress Negative BF
11591 D305 scZDVþsdNVP Malnutrition Negative BF
BF, breast-feeding; FF, formula-feeding; ND, not documented (infant not seen in clinical center, but death reported by the mother); SIDS, sudden infant death syndrome.
doi:10.1371/journal.pmed.0040257.t005
Table 6. Pregnant Women Initiating HAART and Requiring ARV Drug Change before Delivery in the MTCT-Plus Program in Abidjan,
Co ˆte d’Ivoire, 2003–2006
ID # CD4 T
cells/mm
3a
WHO
Staging
a
First Line
ARV Regimen
Gestational
Age (weeks)
a
Days on
Treatment
Reason for
Drug Change
New ARV
Regimen after
Drug Change
b
Infection Status
of Child at 4
Weeks (BF or FF)
10487 309 2 ZDVþ3TCþNVP 29 44 Pulmonary tuberculosis ZDVþ3TCþEFV HIV-infected (FF)
10039 328 2 ZDVþ3TCþNVP 26 35 Mucocutaneous rash
to NVP grade 3
ZDVþ3TCþNLF HIV-negative (FF)
10115 329 2 ZDVþ3TCþNVP 28 110 Mucocutaneous rash
to NVP grade 3
ZDVþ3TCþNLF HIV-negative (BF)
10274 206 2 ZDVþ3TCþNVP 29 27 Mucocutaneous rash
to NVP grade 3
ZDVþ3TCþNLF HIV-negative (FF)
10226 146 1 ZDVþ3TCþNVP 25 34 Mucocutaneous rash
to NVP grade 3
ZDVþ3TCþNLF HIV-negative (BF)
10725 16 2 ZDVþ3TCþNVP 23 42 Mucocutaneous rash
to NVP grade 3
ZDVþ3TCþNLF Stillborn
10228 68 2 ZDVþ3TCþNVP 26 85 Severe anaemia grade 4 D4Tþ3TCþNVP HIV-negative (FF)
10180 111 2 ZDVþ3TCþNVP 30 64 Liver toxicity grade 4
(.503 normal value)
ZDVþ3TCþABC HIV-negative (BF)
10341 252 3 ZDVþ3TCþNVP 29 15 Liver toxicity grade 4
(.53 normal value)
ZDVþ3TCþNLF HIV-negative (BF)
aAt HAART initiation.
bContinued until delivery, except #10487 who reinitiated HAART only 1 mo after delivery.
ABC, abacavir; BF, breast-feeding from birth; EFV, efavirenz; FF, formula feeding from birth.
doi:10.1371/journal.pmed.0040257.t006
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HAART and Pregnancy in Africaadverse events, and one woman had severe anaemia with
associated clinical symptoms. However, the diagnosis of
severe liver toxicity requires frequent laboratory monitoring
during pregnancy. Previous reports on adverse events in
pregnant women in Mozambique [15], Kenya [33], and
Thailand [34] noted that rates of serious hepatic or cutaneous
adverse events among pregnant women receiving NVP-
containing HAART were comparable to those observed in
nonpregnant individuals. Liver toxicity, as indicated by serial
liver function tests, was reported in 6.3% of 606 women in the
DREAM cohort who were systematically treated by HAART in
Mozambique [35]. In our study, we found a rate of 2% of liver
toxicity in HAART-treated pregnant women with advanced
disease.
We also found that the rate of low birth weight in infants
born to mothers treated with HAART was signiﬁcantly
greater than among those exposed to scARV regimens for
PMTCT. HAART exposure has been associated with prema-
turity in some series [16,36] while other studies have found no
association [37,38]. Low birth weight might be related to the
fact that the mothers had more advanced HIV disease, rather
than being a direct effect of HAART itself. Further assess-
ments of these infant outcomes are underway in our cohort
[39].
The main limitation of our study is the cohort sample size,
with relatively small numbers per treatment group, thus
affecting the precision of some MTCT rates and the power to
fully perform statistical comparisons between groups. How-
ever, we were able to document that the upper conﬁdence
limit of the cumulative MTCT rate at 12 mo was less than 7%
in the HAART-treated population where breast-feeding was
commonly practiced for 5 mo, whereas natural risk may have
exceeded 30% [10,11]. Also this study is not a comparative
study, but a description of two tiers with one group receiving
HAART and another group a short-course of ARVs for
PMTCT based on HIV disease staging. Thus, comparisons
between the two tiers should be interpreted with caution. A
more convincing group for the comparison would be a group
of HIV-infected pregnant women eligible for ART who did
not receive it. However, it would be unethical to perform
such a study in a setting where HAART is available for women
who meet eligibility criteria.
Our team has recently summarized available historical data
on HIV-infected pregnant women eligible for ART in the
same Abidjan population [40]. We estimated the transmission
rate at 6 wk at 26.2% in such women having received
antepartum a short-course regimen of 4 wk of ZDV alone and
practicing predominant breast-feeding. In a comparable
group of ART-eligible women who had received 4 wk of
ZDV and sdNVP, with short-term breast-feeding, this rate was
10.1%. At 6 mo the corresponding transmission rates were
41.6% and 15.9%, respectively. It is important to note that, in
the current study, the infant HIV-free survival rates in the
two groups was 11.2% (HAART tier) and 12.1% (scARV tier),
not different between infants born from women with high or
low risk of HIV transmission. It remains unclear, however,
whether the beneﬁts of maternal HAART were counter-
balanced by their effect on infants such as early neonatal
death in association with prematurity.
This study has several strengths. First, retention was high,
with the ﬁnal HIV status available in more than 86% of live
births and only 2% of infants lost to follow-up among
HAART-treated mothers. Second, the high level of adherence
achieved is a likely explanation for the low rate of MTCT in
the HAART-treated tier. Finally, we demonstrated that it is
feasible to screen pregnant women for HIV, assess disease
status by performing CD4 T cell counts, and quickly initiate
HAART. Those who did not require HAART were treated
with standard scART regimens for PMTCT, and the vast
majority of women and their families were engaged in long-
term HIV services. This outcome further demonstrates that
PMTCT is an excellent entry point for women and families in
HIV care and treatment.
In summary, a two-tiered approach to PMTCT, in which
pregnant women with advanced HIV disease receive HAART,
and those with less advanced disease receive scARV regimens
for PMTCT, was safe during pregnancy and highly effective
for the prevention of peripartum and postnatal transmission
in an African population. While further investigations in
other larger or pooled studies are needed to further explore
the balance of beneﬁts and risks related to HAART in breast-
feeding mothers, our results provide evidence supporting the
most recent WHO guidelines [14]. n
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Editors’ Summary
Background Effective treatments are available to prevent AIDS in people
who are infected with HIV, but not everyone with HIV needs to take
medication. Usually, anti-HIV medication is recommended only for those
whose immune systems have been significantly affected by the virus, as
evidenced by symptoms or by the results of a blood test, the CD4
lymphocyte (‘‘T cell’’) count. Treating HIV usually requires a combination
of three or more medications. These combinations (called HAART) must
be taken every day, can cause complications, and can be expensive.
Worldwide, more than half a million children became infected with
HIV each year. Most of these children acquire HIV from their mothers
during pregnancy or around the time of birth. If a pregnant woman with
HIV takes HAART, her chances of passing HIV to the baby are greatly
reduced, but the possible side effects of HAART on the baby are not
known. Also, most transmission of HIV from mothers to babies occurs in
poor countries where supplies of HAART are limited. For these reasons,
World Health Organization (WHO) does not recommend that every
pregnant woman receive HAART to prevent HIV transmission to the
baby, unless the woman needs HAART for her own health (for example if
her T cells are low or she has severe symptoms of HIV infection). For
pregnant women with HIV who do not need to take HAART for their own
health, less complicated treatments, involving a short course of one or
two HIV drugs, can be used to reduce the risk of passing HIV to the baby.
Why Was This Study Done? The WHO recommendations for HAART in
pregnancy are based on the best available evidence, but it is important
to know how well they work in actual practice. The authors of this study
were providing HIV treatment to pregnant women with HIV in West
Africa through an established clinic program in Abidjan, Co ˆte d’Ivoire,
and wanted to see how well the WHO recommendations for HAART or
short-course treatments, depending on the mother’s condition, were
working to protect babies from HIV infection.
What Did the Researchers Do and Find? The researchers studied 250
HIV-infected pregnant women who received HIV medications in the
Abidjan program between mid-2003 and mid-2005. In accordance with
WHO guidelines, 107 women began HAART for their own health during
pregnancy, and 143 women did not qualify for HAART but received
other short course treatments (scARV) to prevent HIV transmission to
their babies. The authors monitored mothers and babies for treatment
side effects and tested the babies for HIV infection up to age 1 y.
They found that HAART was relatively safe during pregnancy,
although babies born to women on HAART were more likely (26.3%)
to have low birth weight than babies born to women who received
scARV (12.4%). Also, 7.5% of women on HAART developed side effects
requiring a change in their medications. Combining the results from
HAART and scART groups, the chance of HIV transmission around the
time of birth was 2.2%, increasing to 5.7% at age 1 y. (Three-quarters of
the infants were breast-fed; safe water for mixing formula was not
reliably available.) The study found no difference in risk of HIV infection
between babies whose mothers received HAART and those whose
mothers received scARV according to guidelines.
What Do These Findings Mean? These results support the safety and
effectiveness of the WHO two-tiered approach for preventing mother-
to-child transmission. This study was not designed to compare HAART to
scART directly, because the women who received HAART were the ones
with more advanced HIV infection, which might have affected their
babies in many ways.
Compared to earlier pregnancy studies of HAART in rich countries,
this study of the WHO approach in West Africa showed similar success in
protecting infants from HIV infection around the time of birth.
Unfortunately, because formula feeding was not generally available in
resource-limited settings, protection declined over the first year of life
with breast-feeding, but some protection remained.
This study confirms that close monitoring of pregnant women on
HAART is necessary, so that drugs can be changed if side effects
develop. The study does not tell us whether using scARV in pregnancy
might change the virus in ways that would make it more difficult to treat
the same women with HAART later if they needed it. The reason for low
birth weight in some babies born to mothers on HAART is unclear. It
may be because the women who needed HAART had more severe
health problems from their HIV, or it may be a result of the HAART itself.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0040257.
  World Health Organization has a page on prevention of
mother-to-child transmission of HIV
  ‘‘Women, Children, and HIV’’ is a resource site from the Franc ¸ois
Xavier Bagnoud Center and UCSF
  The MTCT-Plus initiative at Columbia University supports the
programs in Abidjan
PLoS Medicine | www.plosmedicine.org August 2007 | Volume 4 | Issue 8 | e257 1373
HAART and Pregnancy in Africa